NP-G2-044

N/A

Report date: 2025/08/08 20:01:41
NME

Base Information

Drug NameNP-G2-044
Drug Alias NameDC-05F-01NP-G2-044
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFascin inhibitors
TargetsFascin
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisProstatic Neoplasms +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesNovita Pharmaceuticals Inc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesNovita Pharmaceuticals IncBeijing Shuanghe Runchuang Technology Co LtdChina Resources Double-Crane Pharmaceutical Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursNeoplasm MetastasisSmall Cell Lung Carcinoma +[4] 
Inactive IndicationsProstatic NeoplasmsLung NeoplasmsPancreatic Neoplasms +[7] 

Other Information

ATC CodeN/A
Related LinksN/A